Gossamer Bio, Inc.

As of October 10, 2025, Gossamer Bio, Inc. shows a mildly bullish trend overall, with positive momentum from MACD and Bollinger Bands, but mixed signals from Dow Theory and OBV suggest caution.

As of October 10, 2025, Gossamer Bio, Inc. shows a mildly bullish technical trend, supported by bullish MACD and Bollinger Bands, despite mixed signals from Dow Theory and OBV, while significantly outperforming the S&P 500 year-to-date but underperforming over the last month.

As of August 21, 2025, Gossamer Bio, Inc. shows a bullish technical trend with strong daily moving averages and weekly MACD indicators, despite a bearish monthly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 240.48% compared to 12.22%.

As of August 12, 2024, Gossamer Bio, Inc. is considered a risky investment due to its negative valuation ratios and poor long-term performance, despite a strong year-to-date return.

As of August 12, 2024, Gossamer Bio, Inc. is rated "risky" and considered overvalued due to significant financial distress, with key ratios indicating poor performance compared to peers like Rigel Pharmaceuticals, despite a strong year-to-date return of 51.45%.

As of June 2, 2025, the technical trend has shifted to bullish, supported by strong indicators like a bullish weekly MACD, bullish daily moving averages, and positive momentum from the KST on both weekly and monthly charts.

As of March 2022, Gossamer Bio, Inc.'s management team includes Mr. Faheem Hasnain as Chairman, President, and CEO, along with independent directors Dr. Joshua Bilenker, Ms. Kristina Burow, Mr. Russell Cox, Dr. Thomas Daniel, and Ms. Renee Gala.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunology, inflammation, and oncology. As of March 2025, it has a market cap of $283 million, with net sales of $10 million and a net loss of $37 million.

As of Jun 18, Gossamer Bio, Inc. has a market capitalization of 283.00 million and reported net sales of 124.59 million with a net profit loss of 51.24 million over the last four quarters. Shareholder's funds were 29.49 million, and total assets were 315.29 million.